Brief: Sino Biopharmaceutical Says NMPA Approves Benmelstobart
07/08/2026 18:38
BRIEF-Sino Biopharmaceutical Says NMPA Approves Benmelstobart Aug 7 (Reuters) - Sino Biopharmaceutical Limited 1177.HK:
NMPA APPROVES BENMELSTOBART WITH CHEMOTHERAPY FOLLOWED BY ANLOTINIB FOR FIRST-LINE SQ-NSCLC
Further company coverage: 1177.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sino Biopharmaceutical
See all newsHong Kong stocks end higher on pharma, tech gains
Hong Kong stocks climb, led by pharmaceutical, tech stocks
Brief: Sino Biopharmaceutical Says China's CDE Accepts NDA For TQH2722 Injection
Brief: Sino Biopharmaceutical China CDE Accepts New Drug Application For TQB2102 Injection
Sino Biopharmaceutical climbs on plan to raise stake in core unit